Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics

Executive Summary

Boehringer Ingelheim Pharmaceuticals Inc. entered into a collaboration with ViraTherapeutics GMBH to develop a next generation oncolytic virus platform based on ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) currently in preclinical development for solid cancers.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes M&A Option
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register